Purpose: We aimed to compare the effectiveness of intranasal desmopressin and doxazosin treatmentsin patients with nocturia and benign prostatic hyperplasia (BPH).
Material and Methods: Thirty one men with BPH and three or more episodes of nocturia wererandomized to receive 2 mg doxazosin at night for two weeks increasing to 4 mg for a further twoweeks versus 20 μg intranasal desmopressin at night. For all patients, number of nocturia, urinaryflow rate, residual urine volume and quality of life score were checked. Outcomes were measured attwo months. The comparison of before and after treatment changes between the groups were doneby student’s t-test.
Results: In doxazosin group, mean number of nocturia were 3.2 ± 0.4 (3-4 times) times per night and1.2 ± 0.8 (0-3 times) times per night before and after treatment, respectively. In desmopressin group,mean number of nocturia were 3.4 ± 0.5 (3-4 times) and 1.5 ± 0.6 (1-3 times) times per night beforeand after treatment, respectively. In doxazosin group, mean residual urine volumes were 44.3 ± 35.9ml (range 0-120 ml) and 23.1 ± 18.8 ml (range 0-50 ml) before and after treatment, respectively. Indesmopressin group, mean residual urine volumes were 36.6 ± 32.4 ml (range 0-120 ml) and 14.0 ±26.9 ml (range 0-90 ml) before and after treatment, respectively. Improvements in number of nocturia,residual urine volume, quality of life scores and peak urinary flow rates weren’t statisticallysignificant between two groups, whereas change in international prostate symptom score (IPSS) scorewas more significant in doxazosin group.
Conclusion: Intranasal desmopressin, is an effective symptomatic treatment of men with BPH complainingof nocturia, as well as doxazosin treatment.
Written by:
Ceylan C, Ceylan T, Doluoglu OG, Yuksel S, Agras K. Are you the author?
Clinic of Urology, Konya Numune Hospital, Konya- Turkey.
Reference: Urol J. 2013 Sep 26;10(3):993-8.
PubMed Abstract
PMID: 24078508
